BioCentury | May 20, 2020
Product Development

BARDA takes steps to secure supply chain as more companies look to scale up manufacturing

...for ulcerative colitis. The small molecule blocks viral replication by binding CBC, and also upregulates miR-124...
...cell therapy derived from human bone marrow. Targets CBC - Cap binding complex miR-124 - MicroRNA-124...
BioCentury | May 15, 2020
Product Development

Repurposed autoimmune therapies head for controlled COVID-19 studies in Europe

...which was initially developed for HIV, blocks viral replication by binding CBC. ABX464 also upregulates miR-124...
...Protein Expression” ). Targets CBC - Cap binding complex DHODH - Dihydroorotate dehydrogenase miR-124 - MicroRNA-124 Elizabeth...
BioCentury | Jan 15, 2019
Distillery Therapeutics

Infectious disease

...Alexander G. Pletnev, National Institutes of Health (NIH), Bethesda, Md. email: apletnev@niaid.nih.gov Claire Quang National Institutes of Health MicroRNA-124 (miR-124) MicroRNA-141...
BioCentury | Sep 27, 2018
Translation in Brief

Twice as splice

...splicing of a long non-coding RNA (lncRNA) containing the sequence for the “very potent anti-inflammatory” microRNA-124 (miR-124)...
...intestinal viral reservoirs in HIV patients, and the company’s data showing low intestinal expression of miR-124...
...HIV and ulcerative colitis patients. Abivax also has preclinical and clinical data demonstrating ABX464 normalizes miR-124...
BioCentury | Sep 7, 2018
Clinical News

Abivax's ABX464 improves mucosal healing, Mayo Score in Phase IIa for UC

...binding complex (CBC) Indication: Treat moderate to severe ulcerative colitis Endpoint: Safety; IL-22 expression rate, microRNA-124...
BioCentury | Jan 13, 2017
Emerging Company Profile

Conditional replication

Oncorus Inc. has devised a method to restrict replication of oncolytic viruses to tumor cells without deleting viral genes. The approach could create viruses that are more potent and selective than attenuated viruses in the...
BioCentury | Dec 10, 2015
Distillery Therapeutics

Therapeutics: MicroRNA-124 (miR-124)

...suggest miR-124 could help treat castration-resistant prostate cancer (CRPC). In human prostate cancer cell lines, miR-124...
...bicalutamide decreased proliferation compared with either agent alone. In a human cell-based model of CRPC, miR-124...
...injection of miR-124 decreased tumor growth compared with a scrambled miRNA, and intratumoral injection of miR-124...
BioCentury | Nov 20, 2014
Distillery Techniques

Technology: Drug platforms

...generate new cellular therapies and models of neurological disease. Expression of microRNA-9 (miR-9), miR-9* and miR-124...
BioCentury | Dec 15, 2011
Distillery Therapeutics

Indication: Cancer

...factor 4a (HNF4A; TCF); microRNA-124 (miR-124) Mouse and patient sample studies suggest increasing signaling in the HNF4A-miR-124...
...treatment with miR-124 prevented tumor growth compared with control miRNA treatment. Next steps include evaluating miR-124...
BioCentury | Aug 18, 2011
Distillery Techniques

Technology: Drug platforms

...of reverting cells to induced pluripotent stem (iPS) cells. In human fibroblasts, forced expression of microRNA-124 (miR-124)...
Items per page:
1 - 10 of 13